Transition from ziprasidone im to oral formulation in agitated patients with acute exacerbation of schizophrenia: an open trial
Articolo
Data di Pubblicazione:
2011
Citazione:
Transition from ziprasidone im to oral formulation in agitated patients with acute exacerbation of schizophrenia: an open trial / A. Mautone, S. Scarone. - In: PHARMACOPSYCHIATRY. - ISSN 1439-0795. - 44:5(2011 Jul), pp. 173-178.
Abstract:
Introduction: A transition from IM to oral formulation of an antipsychotic agent is often required during the long-term management of schizophrenia. This multicenter trial evaluates the IM/oral sequential administration of ziprasidone in agitated subjects with an exacerbation of schizophrenia.
Methods: Adult patients requiring IM therapy for schizophrenic symptoms were assigned to IM ziprasidone 10 mg for 3 days, followed by oral ziprasidone (initial dose: 80 mg/day) for 8 weeks. The primary efficacy outcomes were the change in the total PANSS and in the CGI-S scores vs. baseline values.
Results: In total, 150 patients were included in the study. A decline in the PANSS and CGI-S scores was observed throughout the study (p < 0.0001 vs. baseline): these reductions became significant at the point of transition from IM to oral formulation (p < 0.0001 vs. baseline).
Discussion: Even with the limitations of any non-comparative study, these results suggest that the IM/oral sequential administration of ziprasidone is an effective and well tolerated therapeutic option in the management of acute exacerbations of schizophrenia in agitated patients.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
acute exacerbation; antipsychotic agents; schizophrenia; transition; ziprasidone
Elenco autori:
A. Mautone, S. Scarone
Link alla scheda completa: